C
Cerebral Therapeutics
A Clinical-stage pharmaceutical company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy
About Cerebral Therapeutics
Cerebral Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, directing its efforts toward developing treatments for severe neurological conditions. The company was founded in February 2018 by Dr. Dan Abrams, who brings a unique combination of experience as both a neurosurgeon and a psychiatrist. His prior experience includes founding Sierra Neuropharmaceuticals and serving as the head of Neurosurgery at St. Joseph's Hospital in Denver, providing him with extensive expertise in implantable CNS devices and pharmaceuticals for brain diseases.
The company's core focus is on addressing refractory epilepsy, a condition where patients' seizures are not controlled by existing medical or surgical options. Cerebral Therapeutics is pioneering the use of intracerebroventricular (ICV) therapies, a method that delivers medication directly into the central nervous system. This approach is designed to overcome the limitations of conventional oral medications by bypassing the blood-brain barrier, which can increase the drug's effectiveness at the target site while minimizing systemic side effects and improving patient adherence to treatment regimens. The business model centers on the development and eventual commercialization of these novel drug-device combination therapies. Collaborations with other biopharmaceutical companies are also part of their strategy to advance their pipeline.
The company's main product candidate is CT-010, a proprietary formulation of valproic acid delivered via its proprietary ICVRx™ technology. This system uses a surgically implanted and refillable catheter and pump to provide a continuous, micro-dose infusion of the therapeutic drug directly to the ventricles of the brain. The company has advanced CT-010 into clinical trials, including a Phase 2b double-blind, randomized, placebo-controlled study for treating uncontrolled seizures in patients with medically refractory epilepsy. The company has successfully raised significant capital to fund these developments, including a $40 million Series C financing round in June 2022, bringing its total funding to over $85 million across multiple rounds from investors such as Lynx Capital, RA Capital Management, and Vivo Capital.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 20
- Open positions
- None listed
- Dealroom signal
- 57.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Jul 2022 | $32K | — | Innovation Connections | — |
| SERIES COther financing | Jun 2022 | $40M | $160M | RA Capital Management · Lynx1 Capital Management · Granite Point Capital · Vivo Capital | ↗ |
Growth signals
Latest recorded traffic for Cerebral Therapeutics is 2.2K monthly website visits, down 4.3% over the last three months. Cerebral Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Cerebral Therapeutics in the Aurora ecosystem
The Cerebral Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Innovation Connections
Series A3 investors entered at this stage
- GCGranite Point Capital
Vivo Capital
RA Capital Management
Series B and later2 investors entered at this stage
- LMLynx1 Capital Management
Perceptive Advisors
Other known investors1 additional known investor
University of Colorado
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cerebral Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cerebral Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









